A highly selective and potent HPK1 inhibitor enhances immune cell activation and induces robust tumor growth inhibition in a murine syngeneic tumor model

被引：0
|
作者：
Ciccone, D. [1 ]
Lazari, V. [2 ]
Linney, I. [2 ]
Briggs, M. [2 ]
Carreiro, S. [1 ]
Waddell, I. [2 ]
Hill, C. [2 ]
Loh, C. [1 ]
Tummino, P. [1 ]
Collis, A. [1 ]
Kaila, N. [1 ]
机构：
[1] Nimbus Therapeut, Res & Dev, Cambridge, MA USA
[2] Charles River Labs, Res, Chesterford Pk, England
来源：
EUROPEAN JOURNAL OF CANCER | 2020年 / 138卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
46
引用
收藏
页码：S20 / S20
页数：1
相关论文
共 50 条
  • [1] A HIGHLY SELECTIVE AND POTENT HPK1 INHIBITOR ENHANCES IMMUNE CELL ACTIVATION AND INDUCES ROBUST TUMOR GROWTH INHIBITION IN A MURINE SYNGENEIC TUMOR MODEL
    Ciccone, David
    Lazari, Vad
    Linney, Ian
    Briggs, Michael
    Carreiro, Samantha
    McElwee, Joshua
    Waddell, Ian
    Hill, Chris
    Loh, Christine
    Tummino, Peter
    Collis, Alan
    Kaila, Neelu
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A411 - A411
  • [2] A highly potent HPK1 inhibitor augments immune cell activation and anti-tumor immunity in a syngeneic tumor mouse model
    Liu, Hao
    Wu, Lei
    Feng, Song
    Huang, Wei
    Li, Huijuan
    Lin, Jing
    Liu, Yangyang
    Mei, Liufeng
    Ren, Baoqi
    Xie, Julie
    Yao, Lili
    Zhong, Wenge
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [3] Mechanistic understanding of HPK1 inhibition on enhanced human T cell activation and tumor immunity in a syngeneic model.
    Ciccone, David
    Lazari, Vad
    Linney, Ian
    Briggs, Michael
    Carreiro, Samantha
    Loh, Christine
    Tummino, Peter
    McElwee, Joshua
    Collis, Alan
    Kaila, Neelu
    CANCER RESEARCH, 2021, 81 (13)
  • [4] BB3008, a potent and selective small molecular HPK1 inhibitor effective in multiple syngeneic tumor models
    Duan, Gongping
    Li, Min
    Zhang, Xingmin
    CANCER RESEARCH, 2023, 83 (08)
  • [5] Pharmacologic inhibition of HPK1 kinase activity enhances immune cell activation and T cell mediated anti-tumor activity
    Lee, Jacob S.
    Toy, Pamela
    Min-Oo, Gundula
    Lee, Tony
    Salvo, Patrick
    Belzile, JeanPhilippe
    Clancy, Sheila
    Nazareno, Jonathan
    Xu, Mengshu
    Xing, Weimei
    Giacomini, Marilyn
    Santos, Rex
    Stapleton, Lance
    Wang, Adele
    Juric, Vladislava
    Mitchell, Scott A.
    Kuhne, Michelle
    CANCER RESEARCH, 2022, 82 (12)
  • [6] First disclosure of a highly potent and selective HPK1 inhibitor that rescues T cell exhaustion
    Mele, Deanna A.
    Grimster, Neil
    Bommakanti, Gayathri
    Shields, Jason
    Morrill, Lucas
    Giblin, Kathryn
    SanMartin, Maryann
    Wang, Yanjun
    Ye, Minwei
    KarapaReddy, Iswarya
    Song, Kun
    Proia, Theresa
    Hariparsad, Niresh
    Richards, Ryan
    Luheshi, Nadia
    Barry, Simon T.
    Fawell, Stephen
    CANCER RESEARCH, 2023, 83 (07)
  • [7] Highly potent, orally active novel small-molecule HPK1 inhibitor DS21150768 induces anti-tumor responses in multiple syngeneic tumor mouse models
    Setsu, Genzui
    Goto, Megumi
    Ito, Kentaro
    Taira, Tomoe
    Miyamoto, Masaya
    Watanabe, Tomohiro
    Taniguchi, Toru
    Umezaki, Yuma
    Nakazawa, Yusuke
    Uesugi, Shuhei
    Mori, Kazuki
    Horiuchi, Takao
    Obuchi, Wataru
    Minami, Masako
    Shimada, Takashi
    Wada, Chisa
    Yoshida, Takanori
    Higuchi, Saito
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2023, 961
  • [8] RGT-264 a highly potent, selective and orally bioavailable HPK1 (MAP4K1) inhibitor augments immune activation and anti-tumor immunity
    Xiao, F.
    Liu, H.
    Wu, L.
    Feng, S.
    Liu, Y.
    Xiao, H.
    Li, H.
    Huang, W.
    Ren, X.
    Ren, B.
    Yao, L.
    Lin, J.
    Zhong, W.
    Xie, Z.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S172 - S173
  • [9] HPK1 inhibition enhances T cell activation and relieves the immunosuppressive phenotype of inhibitory signals found in the tumor microenvironment
    Singh, Rajesh K.
    Rayaji, Rameshwari
    Patel, Bindi
    Zhang, Kristen
    Marubayashi, Sachie
    Cho, Soonweng
    Garrido-Shaqfeh, Stefan
    Kulusich, Joseph
    Meleza, Cesar
    Tibrewal, Nidhi
    Thomas, Joice
    Nareddy, Pradeep
    Sharif, Ehesan
    Zhao, Sharon
    Green, David
    Leleti, Manmohan R.
    Powers, Jay P.
    DiRenzo, Daniel
    Walters, Matthew J.
    CANCER RESEARCH, 2022, 82 (12)
  • [10] Discovery of LXRβ selective agonists promote immune cell activation and induce tumor growth inhibition in syngeneic tumor model.
    Pujala, Brahmam
    Sathe, Balaji Dashrath
    Gupta, Ashu
    Danodia, Abhinandan
    Soni, Sanjeev
    Kumar, Vivek
    Saeed, Uzma
    Chakravarty, Sarvajit
    CANCER RESEARCH, 2022, 82 (12)
12345